Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.66 |
| ▸ | MMP3 | P08254 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748580 | 0.83 | WDR5 (0.56) | PLK1MMP3HDAC8POLBKDM4E | |
| SCHEMBL10719823 | 0.83 | LDHA (0.59) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL11474339 | 0.83 | PLK1 (0.53) | PLK1MMP3HDAC8POLBKDM4E | |
| SCHEMBL6636042 | 0.83 | PLK1 (0.62) | PLK1MMP3HDAC8POLBKDM4E | |
| SCHEMBL6748722 | 0.82 | MAPT (0.61) | POLBKDM4EMEN1KMT2AMAPT | |
| SCHEMBL10587317 | 0.82 | PLK1 (0.66) | PLK1MMP3HDAC8POLBKDM4E | |
| SCHEMBL161966 | 0.81 | KDM4E (0.49) | PLK1MMP3HDAC8POLBKDM4E | |
| SCHEMBL28609369 | 0.81 | POLB (0.46) | PLK1MMP3HDAC8POLBKDM4E | |
| SCHEMBL6844201 | 0.80 | KDM4E (0.48) | PLK1MMP3HDAC8POLBKDM4E | |
| SCHEMBL9829318 | 0.80 | PLK1 (0.54) | PLK1MMP3HDAC8NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362190-A | Preparation method of polysubstituted olefin | 广东工业大学 | 2024-01-09 | — | — | CN | claimed |
| CN-117362190-A | Preparation method of polysubstituted olefin | 广东工业大学 | 2024-01-09 | — | — | CN | disclosed |
| US-9464064-B2 | HCV helicase inhibitors and methods of use thereof | UNIVERSITY OF KANSAS (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | UWM RESEARCH FOUNDATION, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050038019-A1 | Hydroxy substituted amides for the treatment of alzheimer's disease | PHARMACIA & UPJOHN | 2005-02-17 | — | — | US | disclosed |
| EP-1443923-A1 | HYDROXY SUBSTITUTED AMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003037325-A1 | HYDROXY SUBSTITUTED AMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-0695184-B1 | HIV PROTEASE INHIBITORS | AGOURON PHARMA (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5863950-A | AMIDES OR THIO AMIDE COMPOUNDS WITH HYDROXY OR ETHER GROUPS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5714518-A | HIV protease inhibitors and methods of making the same | AGOURON PHARMACEUTICALS (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0695184-A4 | HIV PROTEASE INHIBITORS | AGOURON PHARMA (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0695184-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-07 | — | — | EP | disclosed |
| WO-1994015906-A1 | HIV PROTEASE INHIBITORS AND THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015608-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0068219-B1 | PROCESS FOR THE SIMULTANEOUS PREPARATION OF CARBOXYLIC ACIDS AND N-TERT,-ALKYL AMINES | BAYER AG (DE) | 1984-08-29 | — | — | EP | disclosed |
| EP-0068219-A1 | Process for the simultaneous preparation of carboxylic acids and N-tert,-alkyl amines | BAYER AG (DE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | DHX15, DDX5, DHX35 | PLK1 903/4885MMP3 2058/4885HDAC8 2256/4885 |
| US-20050038019-A1 | Hydroxy substituted amides for the treatment of alzheimer's disease | BACE1, APP, BACE2 | PLK1 3870/4885MMP3 689/4885HDAC8 465/4885 |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | PLK1 2764/4885MMP3 288/4885HDAC8 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.